Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Angiotensin Converting Enzyme Clear all
Completed Phase 4 Interventional Results available

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

NCT00430638
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide, if necessary, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of DPP4 Inhibition on Growth Hormone Secretion

NCT01701973
View directory record Official record
Conditions
Obesity
Interventions
Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Jul 23, 2026, 9:16 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

NCT01078363
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
ramipril, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

NCT01669434
View directory record Official record
Conditions
Hypotension on Induction
Interventions
ACEI continuation, ACEI omission
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009
View directory record Official record
Conditions
COVID-19
Interventions
Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jul 23, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
rhubarb extract, placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 23, 2026, 9:16 PM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Jul 23, 2026, 9:16 PM EDT
Terminated Phase 3 Interventional

Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

NCT00113698
View directory record Official record
Conditions
Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive
Interventions
Enalapril, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

NCT02122380
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

NCT00848250
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Angiotensin Converting Enzyme Inhibitor, No ACE Inhibitor
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 23, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

NCT01343823
View directory record Official record
Conditions
ACE Inhibitor Induced Angioedema
Interventions
ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
39
States / cities
Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 9:16 PM EDT
Terminated Phase 3 Interventional Results available

VA NEPHRON-D: Diabetes iN Nephropathy Study

NCT00555217
View directory record Official record
Conditions
Kidney Disease, Nephropathy, Type 2 Diabetes
Interventions
losartan, lisinopril
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Jul 23, 2026, 9:16 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 23, 2026, 9:16 PM EDT
Not yet recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

NCT03351478
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 23, 2026, 9:16 PM EDT
Completed No phase listed Observational

Arterial Stiffness and General Anesthesia Induced Hypotension in Patients on Angiotensin-converting Enzyme Inhibitors

NCT02416024
View directory record Official record
Conditions
Hypotension, Arterial Stiffness
Interventions
SphygmoCor system
Device
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 23, 2026, 9:16 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

The RAS, Fibrinolysis and Cardiopulmonary Bypass

NCT00607672
View directory record Official record
Conditions
Coronary Artery Disease, Angiotensin Converting Enzyme, Angiotensin Receptor Blockers, Cardiopulmonary Bypass, Fibrinolysis, Inflammation
Interventions
Placebo, Ramipril, Candesartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jul 23, 2026, 9:16 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

NCT01036659
View directory record Official record
Conditions
Angioedema
Interventions
ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
65 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 23, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945
View directory record Official record
Conditions
Obesity
Interventions
Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Jul 23, 2026, 9:16 PM EDT
Completed No phase listed Observational

Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

NCT06096077
View directory record Official record
Conditions
Angioedema
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 23, 2026, 9:16 PM EDT